CRNX250117P27000
- 0.00
- 0.000.00%
Crinetics Newsroom
Oppenheimer Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $73
Crinetics Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $81
A Quick Look at Today's Ratings for Crinetics(CRNX.US), With a Forecast Between $55 to $92
Crinetics Pharmaceuticals' Atumelnant Trial Data Prompts Hold Rating Amid Efficacy and Safety Concerns
Strong Buy Rating for Crinetics Pharmaceuticals Driven by Promising Atumelnant Data and Market Potential
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Addus Homecare (ADUS)
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $87
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $87
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82
Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Halozyme (HALO) and Crinetics Pharmaceuticals (CRNX)
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82
Promising Outlook for Crinetics Pharmaceuticals' Paltusotine in Phase 3 Trial Drives Buy Rating
Citi Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $74
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $71
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)